The global market for Pharma Sustained Release Agent was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Pharma Sustained Release Agent, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Pharma Sustained Release Agent by region & country, by Type, and by Application.
The Pharma Sustained Release Agent market size, estimations, and forecasts are provided in terms of sales volume (Kiloton) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pharma Sustained Release Agent.
麻豆原创 Segmentation
By Company
Teva Pharmaceutical Industries
Mylan N.V.
Valeant Pharmaceuticals International
Pfizer
Sun Pharmaceutical Industries
Novartis AG
AstraZeneca
GlaxoSmithKline
Allergan
Janssen Pharmaceuticals
Mayne Pharma Group
BASF
International Flavors & Fragrances
Ashland Global
Evonik Industries
Croda International
Gattefosse
Merck KGaA
Segment by Type:
Gelatin
Polymers
Minerals
Sugars
Chitosan
Segment by Application
Pharmaceutical
Health Care
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Pharma Sustained Release Agent manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Pharma Sustained Release Agent in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Pharma Sustained Release Agent in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 麻豆原创 Overview
1.1 Pharma Sustained Release Agent Product Introduction
1.2 Global Pharma Sustained Release Agent 麻豆原创 Size Forecast
1.2.1 Global Pharma Sustained Release Agent Sales Value (2019-2030)
1.2.2 Global Pharma Sustained Release Agent Sales Volume (2019-2030)
1.2.3 Global Pharma Sustained Release Agent Sales Price (2019-2030)
1.3 Pharma Sustained Release Agent 麻豆原创 Trends & Drivers
1.3.1 Pharma Sustained Release Agent Industry Trends
1.3.2 Pharma Sustained Release Agent 麻豆原创 Drivers & Opportunity
1.3.3 Pharma Sustained Release Agent 麻豆原创 Challenges
1.3.4 Pharma Sustained Release Agent 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Pharma Sustained Release Agent Players Revenue Ranking (2023)
2.2 Global Pharma Sustained Release Agent Revenue by Company (2019-2024)
2.3 Global Pharma Sustained Release Agent Players Sales Volume Ranking (2023)
2.4 Global Pharma Sustained Release Agent Sales Volume by Company Players (2019-2024)
2.5 Global Pharma Sustained Release Agent Average Price by Company (2019-2024)
2.6 Key Manufacturers Pharma Sustained Release Agent Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Pharma Sustained Release Agent Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Pharma Sustained Release Agent
2.9 Pharma Sustained Release Agent 麻豆原创 Competitive Analysis
2.9.1 Pharma Sustained Release Agent 麻豆原创 Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Pharma Sustained Release Agent Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pharma Sustained Release Agent as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Gelatin
3.1.2 Polymers
3.1.3 Minerals
3.1.4 Sugars
3.1.5 Chitosan
3.2 Global Pharma Sustained Release Agent Sales Value by Type
3.2.1 Global Pharma Sustained Release Agent Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Pharma Sustained Release Agent Sales Value, by Type (2019-2030)
3.2.3 Global Pharma Sustained Release Agent Sales Value, by Type (%) (2019-2030)
3.3 Global Pharma Sustained Release Agent Sales Volume by Type
3.3.1 Global Pharma Sustained Release Agent Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Pharma Sustained Release Agent Sales Volume, by Type (2019-2030)
3.3.3 Global Pharma Sustained Release Agent Sales Volume, by Type (%) (2019-2030)
3.4 Global Pharma Sustained Release Agent Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Pharmaceutical
4.1.2 Health Care
4.1.3 Others
4.2 Global Pharma Sustained Release Agent Sales Value by Application
4.2.1 Global Pharma Sustained Release Agent Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Pharma Sustained Release Agent Sales Value, by Application (2019-2030)
4.2.3 Global Pharma Sustained Release Agent Sales Value, by Application (%) (2019-2030)
4.3 Global Pharma Sustained Release Agent Sales Volume by Application
4.3.1 Global Pharma Sustained Release Agent Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Pharma Sustained Release Agent Sales Volume, by Application (2019-2030)
4.3.3 Global Pharma Sustained Release Agent Sales Volume, by Application (%) (2019-2030)
4.4 Global Pharma Sustained Release Agent Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Pharma Sustained Release Agent Sales Value by Region
5.1.1 Global Pharma Sustained Release Agent Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Pharma Sustained Release Agent Sales Value by Region (2019-2024)
5.1.3 Global Pharma Sustained Release Agent Sales Value by Region (2025-2030)
5.1.4 Global Pharma Sustained Release Agent Sales Value by Region (%), (2019-2030)
5.2 Global Pharma Sustained Release Agent Sales Volume by Region
5.2.1 Global Pharma Sustained Release Agent Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Pharma Sustained Release Agent Sales Volume by Region (2019-2024)
5.2.3 Global Pharma Sustained Release Agent Sales Volume by Region (2025-2030)
5.2.4 Global Pharma Sustained Release Agent Sales Volume by Region (%), (2019-2030)
5.3 Global Pharma Sustained Release Agent Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Pharma Sustained Release Agent Sales Value, 2019-2030
5.4.2 North America Pharma Sustained Release Agent Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Pharma Sustained Release Agent Sales Value, 2019-2030
5.5.2 Europe Pharma Sustained Release Agent Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Pharma Sustained Release Agent Sales Value, 2019-2030
5.6.2 Asia Pacific Pharma Sustained Release Agent Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Pharma Sustained Release Agent Sales Value, 2019-2030
5.7.2 South America Pharma Sustained Release Agent Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Pharma Sustained Release Agent Sales Value, 2019-2030
5.8.2 Middle East & Africa Pharma Sustained Release Agent Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Pharma Sustained Release Agent Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Pharma Sustained Release Agent Sales Value
6.2.1 Key Countries/Regions Pharma Sustained Release Agent Sales Value, 2019-2030
6.2.2 Key Countries/Regions Pharma Sustained Release Agent Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Pharma Sustained Release Agent Sales Value, 2019-2030
6.3.2 United States Pharma Sustained Release Agent Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Pharma Sustained Release Agent Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Pharma Sustained Release Agent Sales Value, 2019-2030
6.4.2 Europe Pharma Sustained Release Agent Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Pharma Sustained Release Agent Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Pharma Sustained Release Agent Sales Value, 2019-2030
6.5.2 China Pharma Sustained Release Agent Sales Value by Type (%), 2023 VS 2030
6.5.3 China Pharma Sustained Release Agent Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Pharma Sustained Release Agent Sales Value, 2019-2030
6.6.2 Japan Pharma Sustained Release Agent Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Pharma Sustained Release Agent Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Pharma Sustained Release Agent Sales Value, 2019-2030
6.7.2 South Korea Pharma Sustained Release Agent Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Pharma Sustained Release Agent Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Pharma Sustained Release Agent Sales Value, 2019-2030
6.8.2 Southeast Asia Pharma Sustained Release Agent Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Pharma Sustained Release Agent Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Pharma Sustained Release Agent Sales Value, 2019-2030
6.9.2 India Pharma Sustained Release Agent Sales Value by Type (%), 2023 VS 2030
6.9.3 India Pharma Sustained Release Agent Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Teva Pharmaceutical Industries
7.1.1 Teva Pharmaceutical Industries Company Information
7.1.2 Teva Pharmaceutical Industries Introduction and Business Overview
7.1.3 Teva Pharmaceutical Industries Pharma Sustained Release Agent Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Teva Pharmaceutical Industries Pharma Sustained Release Agent Product Offerings
7.1.5 Teva Pharmaceutical Industries Recent Development
7.2 Mylan N.V.
7.2.1 Mylan N.V. Company Information
7.2.2 Mylan N.V. Introduction and Business Overview
7.2.3 Mylan N.V. Pharma Sustained Release Agent Sales, Revenue and Gross Margin (2019-2024)
7.2.4 Mylan N.V. Pharma Sustained Release Agent Product Offerings
7.2.5 Mylan N.V. Recent Development
7.3 Valeant Pharmaceuticals International
7.3.1 Valeant Pharmaceuticals International Company Information
7.3.2 Valeant Pharmaceuticals International Introduction and Business Overview
7.3.3 Valeant Pharmaceuticals International Pharma Sustained Release Agent Sales, Revenue and Gross Margin (2019-2024)
7.3.4 Valeant Pharmaceuticals International Pharma Sustained Release Agent Product Offerings
7.3.5 Valeant Pharmaceuticals International Recent Development
7.4 Pfizer
7.4.1 Pfizer Company Information
7.4.2 Pfizer Introduction and Business Overview
7.4.3 Pfizer Pharma Sustained Release Agent Sales, Revenue and Gross Margin (2019-2024)
7.4.4 Pfizer Pharma Sustained Release Agent Product Offerings
7.4.5 Pfizer Recent Development
7.5 Sun Pharmaceutical Industries
7.5.1 Sun Pharmaceutical Industries Company Information
7.5.2 Sun Pharmaceutical Industries Introduction and Business Overview
7.5.3 Sun Pharmaceutical Industries Pharma Sustained Release Agent Sales, Revenue and Gross Margin (2019-2024)
7.5.4 Sun Pharmaceutical Industries Pharma Sustained Release Agent Product Offerings
7.5.5 Sun Pharmaceutical Industries Recent Development
7.6 Novartis AG
7.6.1 Novartis AG Company Information
7.6.2 Novartis AG Introduction and Business Overview
7.6.3 Novartis AG Pharma Sustained Release Agent Sales, Revenue and Gross Margin (2019-2024)
7.6.4 Novartis AG Pharma Sustained Release Agent Product Offerings
7.6.5 Novartis AG Recent Development
7.7 AstraZeneca
7.7.1 AstraZeneca Company Information
7.7.2 AstraZeneca Introduction and Business Overview
7.7.3 AstraZeneca Pharma Sustained Release Agent Sales, Revenue and Gross Margin (2019-2024)
7.7.4 AstraZeneca Pharma Sustained Release Agent Product Offerings
7.7.5 AstraZeneca Recent Development
7.8 GlaxoSmithKline
7.8.1 GlaxoSmithKline Company Information
7.8.2 GlaxoSmithKline Introduction and Business Overview
7.8.3 GlaxoSmithKline Pharma Sustained Release Agent Sales, Revenue and Gross Margin (2019-2024)
7.8.4 GlaxoSmithKline Pharma Sustained Release Agent Product Offerings
7.8.5 GlaxoSmithKline Recent Development
7.9 Allergan
7.9.1 Allergan Company Information
7.9.2 Allergan Introduction and Business Overview
7.9.3 Allergan Pharma Sustained Release Agent Sales, Revenue and Gross Margin (2019-2024)
7.9.4 Allergan Pharma Sustained Release Agent Product Offerings
7.9.5 Allergan Recent Development
7.10 Janssen Pharmaceuticals
7.10.1 Janssen Pharmaceuticals Company Information
7.10.2 Janssen Pharmaceuticals Introduction and Business Overview
7.10.3 Janssen Pharmaceuticals Pharma Sustained Release Agent Sales, Revenue and Gross Margin (2019-2024)
7.10.4 Janssen Pharmaceuticals Pharma Sustained Release Agent Product Offerings
7.10.5 Janssen Pharmaceuticals Recent Development
7.11 Mayne Pharma Group
7.11.1 Mayne Pharma Group Company Information
7.11.2 Mayne Pharma Group Introduction and Business Overview
7.11.3 Mayne Pharma Group Pharma Sustained Release Agent Sales, Revenue and Gross Margin (2019-2024)
7.11.4 Mayne Pharma Group Pharma Sustained Release Agent Product Offerings
7.11.5 Mayne Pharma Group Recent Development
7.12 BASF
7.12.1 BASF Company Information
7.12.2 BASF Introduction and Business Overview
7.12.3 BASF Pharma Sustained Release Agent Sales, Revenue and Gross Margin (2019-2024)
7.12.4 BASF Pharma Sustained Release Agent Product Offerings
7.12.5 BASF Recent Development
7.13 International Flavors & Fragrances
7.13.1 International Flavors & Fragrances Company Information
7.13.2 International Flavors & Fragrances Introduction and Business Overview
7.13.3 International Flavors & Fragrances Pharma Sustained Release Agent Sales, Revenue and Gross Margin (2019-2024)
7.13.4 International Flavors & Fragrances Pharma Sustained Release Agent Product Offerings
7.13.5 International Flavors & Fragrances Recent Development
7.14 Ashland Global
7.14.1 Ashland Global Company Information
7.14.2 Ashland Global Introduction and Business Overview
7.14.3 Ashland Global Pharma Sustained Release Agent Sales, Revenue and Gross Margin (2019-2024)
7.14.4 Ashland Global Pharma Sustained Release Agent Product Offerings
7.14.5 Ashland Global Recent Development
7.15 Evonik Industries
7.15.1 Evonik Industries Company Information
7.15.2 Evonik Industries Introduction and Business Overview
7.15.3 Evonik Industries Pharma Sustained Release Agent Sales, Revenue and Gross Margin (2019-2024)
7.15.4 Evonik Industries Pharma Sustained Release Agent Product Offerings
7.15.5 Evonik Industries Recent Development
7.16 Croda International
7.16.1 Croda International Company Information
7.16.2 Croda International Introduction and Business Overview
7.16.3 Croda International Pharma Sustained Release Agent Sales, Revenue and Gross Margin (2019-2024)
7.16.4 Croda International Pharma Sustained Release Agent Product Offerings
7.16.5 Croda International Recent Development
7.17 Gattefosse
7.17.1 Gattefosse Company Information
7.17.2 Gattefosse Introduction and Business Overview
7.17.3 Gattefosse Pharma Sustained Release Agent Sales, Revenue and Gross Margin (2019-2024)
7.17.4 Gattefosse Pharma Sustained Release Agent Product Offerings
7.17.5 Gattefosse Recent Development
7.18 Merck KGaA
7.18.1 Merck KGaA Company Information
7.18.2 Merck KGaA Introduction and Business Overview
7.18.3 Merck KGaA Pharma Sustained Release Agent Sales, Revenue and Gross Margin (2019-2024)
7.18.4 Merck KGaA Pharma Sustained Release Agent Product Offerings
7.18.5 Merck KGaA Recent Development
8 Industry Chain Analysis
8.1 Pharma Sustained Release Agent Industrial Chain
8.2 Pharma Sustained Release Agent Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Pharma Sustained Release Agent Sales Model
8.5.2 Sales Channel
8.5.3 Pharma Sustained Release Agent Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
Teva Pharmaceutical Industries
Mylan N.V.
Valeant Pharmaceuticals International
Pfizer
Sun Pharmaceutical Industries
Novartis AG
AstraZeneca
GlaxoSmithKline
Allergan
Janssen Pharmaceuticals
Mayne Pharma Group
BASF
International Flavors & Fragrances
Ashland Global
Evonik Industries
Croda International
Gattefosse
Merck KGaA
听
听
*If Applicable.